Wednesday, July 8, 2026

pharma · Anemia · Anemia Associated With Chronic Kidney Disease · AKBA

Akebia Europe

Akebia Europe clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Cambridge, USA HQ
2007 Founded
271 Employees
Public company Type
AKBA · NYSE Ticker
Company details
Status
Public
HQ
Cambridge, USA
Founded
2007
Employees
271
Programs
25
Drugs
13
Patents
28
Intelligence · Clinical Programs

Akebia Europe projects

7 ClinicalTrials.gov programs sponsored by Akebia Europe.

Akebia Europe has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Epoetin alga (Epogen)/vadadustat

    Akebia Europe Limited

    Anemia Associated With Chronic Kidney Disease

    phase 3 small molecule active

    1 trial
  2. Erythropoiesis-Stimulating Agent (ESA)

    Akebia Europe Limited

    Anemia of Chronic Kidney Disease

    phase 3 small molecule active

    1 trial
  3. Ferric Citrate 1 GM Oral Tablet [AURYXIA]

    Akebia Europe Limited

    Anemia, Iron Deficiency

    phase 3 small molecule completed

    1 trial
  4. Vadadustat

    Akebia Europe Limited

    Anemia of Chronic Kidney Disease

    phase 3 small molecule active

    3 trials
  5. Vadadustat

    Akebia Europe Limited

    Anemia

    phase 3 small molecule completed

    10 trials
  6. Vadadustat

    Akebia Europe Limited

    Anemia Associated With Chronic Kidney Disease (CKD)

    phase 3 small molecule completed

    1 trial
  7. Vadadustat 900mg

    Akebia Europe Limited

    Nonintubated Acute Respiratory Distress Syndrome (ARDS)

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Akebia Europe have?

7 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.